(Q48489668)

12 February 2018

title

Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. (English)

1 reference

12 February 2018

1 reference

1 reference

Leah R Hanson

1

1 reference

12 February 2018

Jared M Fine

2

1 reference

12 February 2018

Dan B Renner

3

1 reference

12 February 2018

Aleta L Svitak

4

1 reference

12 February 2018

Rachel B Burns

5

1 reference

12 February 2018

Thuhien M Nguyen

6

1 reference

12 February 2018

Nathan J Tuttle

7

1 reference

12 February 2018

Dianne L Marti

8

1 reference

12 February 2018

S Scott Panter

9

1 reference

12 February 2018

William H Frey

10

1 reference

12 February 2018

publication date

1 June 2012

1 reference

12 February 2018

Drug delivery and translational research

published in

1 reference

12 February 2018

volume

2

1 reference

12 February 2018

issue

3

1 reference

12 February 2018

page(s)

160-168

1 reference

12 February 2018

https://scigraph.springernature.com/pub.10.1007/s13346-011-0050-2

exact match

0 references

cites work

Intranasal drug delivery for brain targeting.

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Intranasal delivery: physicochemical and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Delivery of interferon-beta to the monkey nervous system following intranasal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Intranasal insulin to improve memory function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Intranasal insulin improves memory in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Multiple pathways of neuroprotection against oxidative stress and excitotoxic injury in immature primary hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Treatment of Alzheimer's disease with clioquinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Reversion of age-related recognition memory impairment by iron chelation in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Intramuscular desferrioxamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Intranasal delivery to the central nervous system: mechanisms and experimental considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

21 January 2018

Iron-chelating therapy

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Intranasal administration of deferoxamine to iron overloaded patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Drug Development Based on the Metals Hypothesis of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-011-0050-2

Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease.

21 January 2018

1 reference

12 December 2020

Metal protein attenuating compounds for the treatment of Alzheimer's disease

1 reference

12 December 2020

Aluminium and the pathogenesis of Alzheimer's disease: a summary of evidence

1 reference

12 December 2020

The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

1 reference

12 December 2020

Drug development based on the metals hypothesis of Alzheimer's disease

1 reference

12 December 2020

Environmental enrichment delays the onset of memory deficits and reduces neuropathological hallmarks in a mouse model of Alzheimer-like neurodegeneration

1 reference

12 December 2020

Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents.

1 reference

12 December 2020

Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway.

1 reference

12 December 2020

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial

1 reference

12 December 2020

10.1007/S13346-011-0050-2

Identifiers

DOI

1 reference

12 February 2018

PubMed ID

25786865

1 reference

12 February 2018